Molecular docking and antihypertensive effects of a novel angiotensin-I converting enzyme inhibitory peptide from yak bone

Xinchang Gao1,2, Fan Bu3, Dalong Yi4, Huaigao Liu4, Zhiying Hou2, Chaoying Zhang1, Chang Wang1, Jin-Ming Lin1, Yali Dang3* and Yufen Zhao1,2*

1Department of Chemistry, Tsinghua University, Beijing, China, 2Institute of Drug Discovery Technology, Ningbo University, Ningbo, China, 3College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, China, 4Anhui Guotai Biotechnology Co., Ltd., Xuancheng, China

A novel angiotensin-converting enzyme (ACE) inhibitory peptide ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPVSAVRA) was purified and identified from yak bone by Electrospray Ionization-Time of Flight-Mass Spectrometry (ESI-TOF-MS). Results in vitro showed that the peptide exhibited strong ACE inhibition activities with an IC50 of 54.22 µM. Molecular docking results showed the binding between the peptide SASVIPVSAVRA and ACE mainly driven by van der Waals forces, hydrogen bonds and metal receptor. Interestingly, the ACE inhibition activities of the peptide increased about 19% after digestion, but none of its metabolites showed stronger activity than it. The in vivo experiment showed that the antihypertensive effect of peptide SASVIPVSAVRA at dose of 30 mg/kg is nearly equal to Captopril at dose of 10 mg/kg to spontaneously hypertensive rats (SHRs). The antihypertensive effect mechanism of SASVIPVSAVRA should be further studied through plasma metabolomics and bioanalysis. Structure analysis of amino acids and peptides produced during digestion may help better understand the antihypertensive effect of peptides.

KEYWORDS
molecular docking, antihypertensive effects, yak bone, ACE inhibitory peptide, digestion

Introduction

Hypertension is the most common chronic disease and a significant threat to cerebrovascular diseases. It usually causes headaches, inattention, memory loss, chest tightness, fatigue, and other symptoms (1).

With the continuous increase in the number of people suffering from hypertension, researchers have paid more attention to the prevention, and the treatment of
hypertension. The renin-angiotensin system (RAS) and kallikrein-kinin system (KKS) play an important role in regulating blood pressure in vivo (2). In RAS, Renin cleaves angiotensinogen to produce the inactive Angiotensin I, and through the action of ACE, which generated Angiotensin II with vascular smooth muscle activity, thereby causing the blood pressure spiked. In KKS, ACE deactivates bradykinin, and bradykinin stabilizes blood pressure by relaxation blood vessels and regulating electrolytes. Unfortunately, synthetic ACE inhibitors (captopril and enalapril) occasionally cause some adverse reactions, such as coughing, allergic reactions, and elevated blood potassium levels (3). More and more attention has been focused on seeking food-derived ACE inhibitory peptides that could lower blood pressure and reduce side effects in recent years. Interestingly, more and more reports appeared about the natural polypeptides with potential ACE inhibitory activity in vitro and in vivo, and they are structurally similar to synthetic drugs (4). These ACE inhibitors are safe without side effects.

Animal bones are an important source of functional peptide (5, 6). Researchers found many food-derived antihypertensive peptides in animals and plants, including fungi, milk, yeast, cheese, fish, and soybeans (7, 8). The ACE inhibitory activities of peptides are nearly related to their unique amino acid composition, such as Pro, Ala, and Val (9). Interestingly, yak bones are also rich in these unique amino acids. Chen et al. (10) reported that yak bones were rich in glycine, alanine, proline and glutamic acid (10). However, there are few reports on the isolation of ACE inhibitory peptide sequences from yak bones. Sun et al. (11) reported an antioxidant peptide GPHGAGGGA from yak bone. Ye et al. (12) reported an peptide GPSGPAGKDGRIQPG from Yak bone with osteoblast-proliferating activity.

This study aims to purify and identified the bioactive peptides from Yak bone, evaluate the antihypertensive effects in vivo, explain the mechanism between peptide and ACE.

Materials and methods

Materials

Yak bone was provided by Anhui Guotai Biotechnology Co., Ltd., Papain (800 U/g proteins), pepsin (25,000 U/mL), pancreatin (800 U/mL), ACE, Hippuryl-histidyl-leucine (HHL), BCA Protein Assay Kit and Sephadex G-25 were purchased from Sigma-Aldrich (St. Louis, MO, USA). All the reagents were of analytical grade.

Preparation of yak bone peptide

One hundred and fifty gram of yak bone powder was dispersed in distilled water with the mass ratio of 1:30, and the content of yak bone protein was 197 g/kg. The hydrolyzed were mixed with papain (800 U/g proteins) at 60°C, 80 r/min for 6 h. After inactivating the enzyme by boiling for 10 min, The mixture was filtered and lyophilized (13).

Peptide separation and purification

The method of Separation and Purification was according to the method of Bu et al. (14) with minor modification (14). The lyophilized samples of the hydrolysate product were dissolved in distilled water to reach 20 mg/mL concentration.
Peptides identification and synthesis

ESI-TOF-MS was used for the identification of peptides from HPLC Fractions as described by Dang et al. (15). Electrospray ionization (ESI) was used in positive ion mode, source temperature was set at 150°C, desolvation temperature was set at 550°C, scan range was m/z 50–1200. The most active fraction (F6) was resuspended in water at a concentration of 1 mg/mL. The filtrate was then analyzed with the ESI-TOF mass spectrometer of the ACQUITY UPLC H-Class HPLC system (Waters, USA). The column used was BEH300 C18 (2.1 × 100 mm; 1.7 µm) (Waters, USA), the flow rate was 0.2 mL/min, and the injection volume was 10 µL. All MS and MS/MS spectra were collected and analyzed using Mass Lynx (Waters version 4.1). The PepSeq program of Biolynx (Waters Corp.) software was used for sequencing. These peptides were custom-synthesized by Sangon Biotech Co., Ltd., (Shanghai, China) (16).

The purity of these peptides was above 99%.

Determination of angiotensin-converting enzyme inhibitory activity

The original ACE Inhibitory Activity method was developed by Cushing and Cheung (17). The ACE inhibitory activity assay used here were performed according to the method of Dang et al. (15). 80 µL of 5 mM HHL (in HEPES buffer containing 300 mM NaCl at pH 8.3) and 30 µL samples were mixed in 37°C water bath for 5 min, 40 µL ACE (0.025 U/mL) was added for incubation for 1 h. The reaction was stopped by adding 250 µL.
of 1 M HCl, they were filtered and measured the ACE inhibitory activity by an Agilent 1260 HPLC system (Agilent Technologies, Karlsruhe, Germany).

\[
\text{ACE Inhibitory activity\%} = \frac{\text{Control} - \text{Sample}}{\text{Control} - \text{Control Blank}} \tag{1}
\]

**In vitro gastrointestinal digestion**

Gastrointestinal digestion was evaluated according to the method of Dang et al. (15) and Mulet-Cabero et al. (18) with minor modification. Simulated gastric juice (pH 2.0) and simulated intestinal fluid mixture (pH 7.6) were added to peptide solution and incubated at 37°C for 2 h, respectively.

**Antihypertensive effect of angiotensin-converting enzyme inhibitory peptide in vivo**

The systolic blood pressure (SBP) changes in the SHRs were measured by the tail-cuff method to determine the antihypertensive effect of ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPSVA) in vivo. Twenty female SHRs,
FIGURE 3
Analysis of peptides SASVIPVSARVA after digestion. (A) 3D waterfall Tic chromatography of the samples. (B) Tic chromatography of the 0.5 h samples. (C) Ms spectrum of peptide SASVIPVSARVA. (D) Ms spectrum of peptide SASVIPVSARV. (E) Ms spectrum of peptide SASVIPVSAR. (F) Ms spectrum of peptide SASVIP. (G) Ms spectrum of peptide AVR. (H) Peak area of Metabolites in digestion samples.
weighing 230 ± 15 g and the SBP exceeding 190 mmHg, were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. (China).

The SHRs were free to eat and drink at 25 ± 4°C and a 40 ± 6% humidity. To get the rats to adapt to the environment, the systolic blood pressure was measured once a day for 1 week. After a week of adaptation, the SHRs were randomly divided into three groups with each group containing 6 SHRs: the control group (sterilized water), captopril group (10 mg/kg captopril BW), SASVIPVSAVRA (30 mg/kg SASVIPVSAVRA BW). The effect of ACE inhibitors on SBP were measured by the Softron BP non-invasive blood pressure monitor (Softron BP-2000, Tokyo, Japan) at 0, 2, 4, and 6 h after oral administration (1). The measurements were repeated five times, the recordings were reported as mean ± standard deviation (SD). All animal procedures used in this trial were approved by the Institutional Animal Care and Use Committee of Hangzhou Medical College (Approval No. ZJCLA-IACUC-20010014).

Angiotensin-converting enzyme inhibition pattern

The ACE inhibition pattern was similar to that used by Zhang et al. (19) with slight modifications. The concentration of HHL was changed to 0.5, 1, and 2 mmol/L, and the concentration of the purified peptide was changed to 0.1 and 0.2 mg/mL.

Molecular docking

The molecular docking was performed using the Discovery Studio software package (Neo Trident Technology Ltd., China) according to the method of Chen et al. (20) with some modifications. The crystal structure of the human ACE-lisinopril complex (108A.pdb) was from RCSB PDB Protein Data Bank. SBD_Site_Sphere was X: 37.8546, Y: 38.1941, Z: 47.2396 and the docking radius was 20 Å.

Statistical analysis

All data were analyzed using SPSS for Windows Version 25.0. The results were based on the mean ± standard deviation of at least three determinations. A P-value of less than 0.05 was considered statistically significant.

Results and discussion

Isolation and purification of angiotensin-converting enzyme peptides

Results showed that the yak bone peptide prepared by section “Preparation of yak bone peptide” had ACE inhibitory activity and its IC₅₀ was 1.47 mg/mL. So the ACE fractions were further separated and purified. Four components of Yak bone peptide were separated by Sephadex G-25 column (Figure 1A). G2 had the highest ACE inhibitory activity with IC₅₀ value of 0.181 mg/mL, while IC₅₀ values of other fractions G1, G3, and G4 were 0.258, 0.459, and 0.563 mg/mL, respectively. So, G2 was chosen for further purification, and the peptides were separated using RP-HPLC (Figure 1B). Finally, the 7 fractions were collected, and F6 had the highest ACE inhibitory activity

![FIGURE 4](http://www.rcsb.org)

Line weaver-Burke plot of ACE activity in the presence of the peptide.
among them (IC$_{50}$ = 0.12 mg/mL). So F6 was collected for further experiment.

**Peptides identification**

Peptides from F6 was identified by ESI-TOF-MS and synthesized by the Sangon Biotech Co., Ltd. The sequence was SASVIPSAVRA. The IC$_{50}$ of ACE inhibitory activity was 54.22 µM. The mass spectrum of this peptide was shown in Figures 2A,B.

It was found that the IC$_{50}$ value of SASVIPSVRA (54.22 µM) was much higher than the reported ACE peptide SGGSYADELCSTAK (0.093 µM) (21) while lower than other peptides, such as QLLLQQ (IC$_{50}$, 75.0 µM) and IVVE (IC$_{50}$, 315.3 µM) (22, 23). Therefore, it was meaningful to study the ACE inhibitory activity of SASVIPSVRA.

The ACE inhibitory Activity of peptides was closely related to hydrophobic amino acid residues, such as Proline, Valine, Serine, Alanine, Leucine and Isoleucine (24). Therefore, the rich hydrophobic amino acids in the peptide SASVIPSVRA may be the main reason for the ACE inhibitory activity. The presence of...
of proline in the sequence may allowed the carboxyl group to interact with the positively charged residues in the active site of the enzyme to contribute to its ACE activity (25).

Generally, the presence of amino acids (Val, Ile) with hydrophobic branches would increase the ACE inhibitory activity (26). Therefore, the Val residue and Ile residue in SASVIPVSAVRA may contribute to the ACE activity of the peptide. Besides, Matsumura et al. (27) reported that the tripeptide VIP extracted from Bonito Bowels Autolysate had strong ACE inhibitory activity. The peptide SASVIPVSAVRA isolated from the yak bone hydrolysate also contained the tripeptide above-mentioned (VIP). The ACE inhibitory activity may also be due to the presence of ACE inhibitor VIP in its structure. However, this peptide still needed further tests on SHRs to determine whether its activity remained in vivo. It was also necessary to determine the digestion stability and the activity of the peptide after digestion. Therefore, it was discussed about the blood pressure inhibitory effect of the peptide in vivo and the simulated digestion results as follows.

**Gastrointestinal digestion of ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPVSAVRA) in vitro**

More and more evidence showed that some bioactive peptides were unstable after digestion (28). Therefore, it is also very important to evaluate the digestive stability of bioactive peptides.

The IC$_{50}$ of SASVIPVSAVRA before and after digestion were 54.22 and 44.06 µM, respectively. The ACE inhibitory activity after digestion increased about 19%. SASVIPVSA, SASVIPVS, SASVIPV, and AVR were found in the digestion sample (Figure 3). The IC$_{50}$ were 102.3, 144.6, 167.6, 213.2 µM.

There is no significant peak of SASVIPVSAVRA found in the digested samples, indicating SASVIPVSAVRA was easily digested by gastrointestinal tract. SASVIPVSA was the main metabolite. The reason for the increased ACE inhibitory activity after the peptide SASVIPVSAVRA digestion needs further investigation.

As reported by Katayama et al. (29), certain peptides had certain resistance to digestive proteases in vivo and could still show strong biological activity. In addition, Long chain peptides are more easily digested into many short peptides, and active peptides are more likely to appear (30). Therefore, in the future, we will further study the transport of peptide in human intestinal CaCo-2 cell monolayers to determine the absorption of the peptide in vitro.

**The angiotensin-converting enzyme inhibition patterns**

Most peptides are in a competitive ACE inhibition pattern, while a small part of them are in a non-competitive ACE inhibition pattern (31). According to the Lineweaver-Burk plots, the ACE inhibition pattern of the peptide was estimated (Figure 4). The increased Km and constant Vmax indicated that SASVIPVSAVRA acted as a competitive ACE inhibitor. This suggested that SASVIPVSAVRA might competitively bind to the catalytic site of ACE to prevent ACE from binding to the substrate (32). Also, Cheung et al. (33) found those peptides containing hydrophobic C-terminal amino acids (such as alanine, phenylalanine and tyrosine) generally performed a competitive inhibition pattern. From our results, the peptide SASVIPVSAVRA had alanine residues at the C-terminal, respectively. This may offer an explanation of why SASVIPVSAVRA exhibited a competitive inhibitor.
Molecular docking simulation

Molecular docking is to explore the binding interactions effect of peptide on ACE. Figure 5A showed the best posture for docking peptide SASVIPVSARVA at the active site of ACE through docking simulation. The mutual binding energy was 134.935 kJ/mol. The docking structure Figure 5B showed that Van der Waals forces, hydrogen bonds and metal receptor were the major binding forces in the interaction between SASVIPVSARVA and ACE.

The peptide existed in the ACE active site's narrow channel and formed 9 hydrogen bonds with ACE. It indicated that the peptide had strong interaction forces with ACE (34). Specifically, the peptide established hydrogen bonds with ACE residues Arg124, Tyr135, Trp220, Ser284, Ala354, Glu384, Ser517, and Arg522, which may be the key residues in ACE binding (35). The active center of ACE comprises zinc ions and three primary active capsules (S1, S2, S3). More studies have shown that high ACE inhibitory activity peptides can directly interact with the ACE Zn(II) (36). This result may offer an clarification of why SASVIPVSARVA displayed high ACE inhibitory activity.

Antihypertensive effects of ser-ala-ser-val-ile-pro-val-ser-ala-val-arg-ala (SASVIPVSARVA) in vivo

The antihypertensive effect of peptide SASVIPVSARVA was evaluated by measuring the changes in SBP in the SHRS within 8 h after administration.

The systolic blood pressure of the negative control group (sterilized water) had no significant change after administration (Figure 6). The SASVIPVSARVA group and the captopril group significantly reduced the SBP of SHRs (Figure 6). A significant antihypertensive effect had been observed within 8 h of administration of the SASVIPVSARVA peptide. Antihypertensive activity peaked at the 6th hour after administration. When the oral dose was 30 mg/kg, the maximum reduction of systolic blood pressure in the sample group and the positive control group was 15.3 and 14.9%, respectively. It was shown that ACE peptide and captopril have similar antihypertensive effects in vitro, suggesting that ACE peptide and captopril were not directly proportional to their antihypertensive abilities in vitro and in vivo, This was consistent with the study by Cao et al. (1). Some chemically synthesized drugs have a substantial effect on lowering the blood pressure in vitro, but their effects in vivo will be weakened (37, 38). Remarkably, Captopril is a chemically designed and commercially used drug. The peptide SASVIPVSARVA also had a blood pressure lowering effect in vivo, so it could provide a reference for the development of new blood pressure lowering drugs. Furthermore, the ACEI peptide IVGRPRHOG from chicken muscle showed similar antihypertensive effect as SASVIPVSARVA, but required a higher dose of 60 mg/kg BW (39).

The peptide SASVIPVSARVA had high ACE inhibitory activity both in vitro and in vivo. The ACE inhibitory activity increased about 19% after digestion, but none of its metabolites showed stronger activity than it. Some hydrophobic amino acids produced during this digestion are worth considering. The relationship between the metabolites of the peptide in blood and effect of antihypertensive effect in vivo should be deeply studied through the plasma metabonomics and bioanalysis.

Conclusion

A novel angiotensin converting enzyme (ACE) inhibitory peptide SASVIPVSARVA was purified and identified from yak bone in this study. The results show that the peptide has strong ACE inhibitory activity in vitro and hypotensive effect in vivo, and has the potential to be developed into antihypertensive drugs.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

Ethics statement

All animal procedures used in this trial were approved by the Institutional Animal Care and Use Committee of Hangzhou Medical College (Approval No. ZJCLA-IACUC-20010014).

Author contributions

YZ and YD contributed to the conception of the study. XG and FB performed the experiment. DY and HL contributed significantly to analysis and manuscript preparation. ZH, CZ, and CW performed the data analyses and wrote the manuscript. XG, J-ML, and YD helped perform the analysis with constructive discussions. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Scientific Research Grant of Ningbo University (215-432000282), the Ningbo Top Talent Project (215-432094250), and the Zhejiang Provincial Administration for Market Regulation (CY202234).
Conflict of interest

Authors DY and HL were employed by Anhui Guotai Biotechnology Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Cao S, Wang Y, Hao Y, Zhang W, Zhou G. Antihypertensive effects in vitro and in vivo of novel angiotensin-converting enzyme inhibitory peptides from bovine bone gelatin hydrolysate. *J Agric Food Chem.* (2020) 68:759–68. doi: 10.1021/acs.jafc.9b05618
2. Fitzgerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. *J Nutr.* (2004) 134:9805–85.
3. Liu C, Fang L, Min W, Liu J, Li HJ. Exploration of the molecular interactions between angiotensin-1 converting enzyme (ACE) and the inhibitory peptides derived from hazelnut (*Corylus heterophylla* Fisch.). *Food Chem.* (2018) 245:471–80. doi: 10.1016/j.foodchem.2018.10.095
4. Liao W, Fan H, Wu J. Egg white-derived antihypertensive peptide IRW (Ile-Arg-Trp) inhibits angiotensin II-stimulated migration of vascular smooth muscle cells via angiotensin type i receptor. *J Agric Food Chem.* (2018) 66:5133–8. doi: 10.1021/acs.jafc.8b00483
5. Bao Y, Yang H, Jing L, Li Z, Jiang Y. Amino acid composition, molecular weight distribution and antioxidant activity of protein hydrolysates of soy sauce lees. *Food Chem.* (2010) 124:551–5.
6. Li F, Jia D, Yao K. Amino acid composition and functional properties of collagen polypeptide from Yak (*Bos grunniens*) bone. *LWT Food Sci Technol.* (2009) 42:945–9. doi: 10.1016/j.lwt.2008.12.005
7. Gallego M, Mora L, Science FT. Health relevance of antihypertensive peptides in foods. *Curr Open Food Sci.* (2017) 19:8–14.
8. Shen S, Chahal B, Majumder K, You SJ, Wu J. Identification of novel antioxidant peptides derived from a thermolytic hydrolysate of ovotransferrin and characterization of antioxidant peptides from yak (*Bos grunniens*) bone hydrolysate. *Food Chem.* (2010) 111:265–73. doi: 10.1016/j.foodchem.2009.07.083.
9. Taga Y, Hayashida O, Ashour A, Amen Y, Kanibuta M, Ogawa-Goto K, et al. Characterization of angiotensin-converting enzyme inhibitory activity of *X. Hap-Gly-type tripeptides: importance of collagen-specific prolyl hydroxylation. J Agric Food Chem.* (2018) 66:8737–43. doi: 10.1021/acs.jafc.8b03648.
10. Chen G, Cheng L, Xu H, Song H, Lv Y, Yang C, et al. Functions of different yak bone peptides. *Int J Food Prop.* (2011) 14:1136–41. doi: 10.1080/1094291100392753
11. Sun X, Wang K, Gao S, Hong H, Zhang L, Liu H, et al. Purification and characterization of antioxidant peptides from yak (*Bos grunniens*) bone hydrolysates and evaluation of cellular antioxidant activity. *J Food Sci Technol.* (2021) 58:3106–19. doi: 10.1007/s13197-020-04814-7.
12. Ye M, Jia W, Zhang C, Shen Q, Zhu L, Wang L, et al. Preparation, identification and molecular docking study of novel osteoblast proliferation-promoting peptides from yak (*Bos grunniens*) bones. *RSC Adv.* (2019) 9:14627–37. doi: 10.1039/ c9ra00454k.
13. Guo Z, Liu C, Hu B, Zhu I, Yang Y, Liu F, et al. Simulated gastrointestinal digestion of yak bone collagen hydrolysates and insights into its effects on gut microbiota composition in mice. *Food Biosci.* (2021) 44:101463. doi: 10.1016/j.foobar.2021.101463.
14. Bu F, Yi D, Zhang H, Li Q, Pan D, Dang Y. Isolation and identification of antioxidant and DPP-IV inhibitory peptide PYPYEPYEPYPY from yak bone hydrolysate. *Food Sci Technol Res.* (2021) 27:441–52. doi: 10.3136/fstr.2021.7441.
15. Pang Y, Zhou T, Hao L, Cao J, Sun Y, Pan D. In vitro and in vivo studies on the angiotensin-converting enzyme inhibitory activity peptides isolated from broccoli protein hydrolysate. *J Agric Food Chem.* (2019) 67:6757–64. doi: 10.1021/acs.jafc.9b01137.
16. Dang Y, Gao X, Ma F, Wu X. Comparison of umami taste peptides in water-soluble extracts of Jinhua and Parma hams. *LWT Food Sci Technol.* (2015) 60:1179–86.
17. Cushman DW, Cheung HC. Spectrophotometric assay and properties of angiotensin-converting enzyme of rabbit lung. *Biochim Biophys Acta.* (1971) 20:1637–48.
18. Mulet-Cabero AJ, Egger I, Portmann R, Menard O, Mazze R, Minekus M, et al. A standardised semi-dynamic in vitro digestion method suitable for food – an international consensus. *Food Funct.* (2020) 11:1702–20. doi: 10.1039/c9fo01293a.
19. Zhang Y, Pan D, Yang Z, Gao X, Dang Y. Angiotensin I-Converting enzyme (ACE) inhibitory and dipeptidyl Peptidease-4 (DPP-IV) inhibitory activity of umami peptides from Rudipate Philippinarum. *LWT* (2021) 144:111265. doi: 10.1016/j.lwt.2021.111265.
20. Chen M, Pan D, Zhou T, Gao X, Dang Y. Novel umami peptide IPIPAIPKT with dual dipeptidyl peptidase-IV and angiotensin I-converting enzyme inhibitory activity. *J Agric Food Chem.* (2021) 69:5463–70. doi: 10.1021/acs.jafc.0c07138.
21. Karami Z, Peighambardoust SH, Hesari J, Akbari-Adergani B, Andre D. Antioxidant, anticancer and ACE-inhibitory activities of bioactive peptides from wheat germ protein hydrolysates. *Food Biosci.* (2019) 32:100450. doi: 10.1016/j.foodbi.2019.100450.
22. Suetsuna K, Chen JR. Identification of angiotensin II-converting enzyme peptides from peptic digest of two microalgae, *Chlorella vulgaris* and *Spirulina platensis*. *Mar Biotechnol.* (2001) 3:305–9. doi: 10.1016/s1088-1301(00)00015-7.
23. Bhaskar B, Ananthanarayan L, Jamdar S. Purification, identification, and characterization of novel angiotensin I-converting enzyme (ACE) inhibitory peptides from alkalase digested horse gram flour. *LWT* (2019) 103:155–61. doi: 10.1016/j.lwt.2018.12.059.
24. Hao L, Gao X, Zhou T, Cao J, Sun Y, Dang Y, et al. Angiotensin I-Converting Enzyme (ACE) inhibitory and antioxidant activity of umami peptides after in vitro gastrointestinal digestion. *J Agric Food Chem.* (2020) 68:8322–41. doi: 10.1021/acs.jafc.0c02797.
25. Mine Y, Shahidi F (Eds.). *Nutraceutical Proteins And Peptides In Health And Disease*. New York, NY: Taylor & Francis Group (2006). p. 269–315.
26. Wu J, Aluko RE, Nakai S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship modeling of peptides containing 4-10 amino acid residues. *QSR Combinat Sci.* (2006) 25:873–80. doi: 10.1002/qss.200630005.
27. Matsumura N, Fujii M, Takeda Y, Sugita K, Shimizu TJ. Angiotensin I-converting enzyme inhibitory peptides derived from bonito bowels autolysate. *Bioch Sci Technol Biochm.* (1993) 57:695–7. doi: 10.1271/bbb.57.695.
28. Yu Y, Jin Y, Wang F, Yan J, Qi Y, Ye M. Protein digestsination analysis reveals the bioactivity of deer antler velvet in simulated gastrointestinal digestion. *Food Res Int.* (2017) 96:182–90. doi: 10.1016/j.foodres.2017.04.002.
29. Katayama K, Mori JT, Kawahara S, Miuke K, Kodama Y, Sugiyama M, et al. Angiotensin-I converting enzyme inhibitory peptide derived from porcine skeletal muscle myosin and its antihypertensive activity in spontaneously hypertensive rats. *J Food Sci.* (2007) 72:5792–6. doi: 10.1111/j.1750-3841.2007.00571.x.
30. Ye Y, Engholm-Keller K, Fang Y, Nielsen CE, Jorda A, Lund MN, et al. UHT treatment and storage of liquid infant formula affects protein digestion and.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
release of bioactive peptides. Food Funct. (2022) 13:344–55. doi: 10.1039/d1fo02619d

31. Li GH, Le GW, Shi YH, Shrestha S. Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr Res. (2004) 24:469–86.

32. Ye S, Chen Q, Li D, Zhou H, Chen Y, Meng C, et al. Isolation and identification of novel angiotensin I-converting enzyme (ACE) inhibitory peptides from Pony Seed and evaluation of the inhibitory mechanisms. J Funct Foods. (2022) 95:105151. doi: 10.1016/j.jff.2022.105151

33. Cheung HS, Wang FL, Ondetti MA, Sabo EF, Cushman DW. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. J Biol Chem. (1980) 255:401–7. doi: 10.1016/s0021-9258(19)86187-2

34. Chaudhary S, Vats ID, Chopra M, Biwas P, Pasha S. Effect of varying chain length between P(1) and P(1') position of tripeptidomimics on activity of angiotensin-converting enzyme inhibitors. Bioorg Med Chem Lett. (2009) 19:4364–6. doi: 10.1016/j.bmcl.2009.05.079

35. Wu Q, Du J, Jia J, Kuang C. Production of ACE inhibitory peptides from sweet sorghum grain protein using alcalase: hydrolysis kinetic, purification and molecular docking study. Food Chem. (2016) 191:48–9. doi: 10.1016/j.foodchem.2015.12.012

36. Jimsheena VK, Gowda LR. Arachin derived peptides as selective angiotensin I-converting enzyme (ACE) inhibitors: structure-activity relationship. Peptides. (2010) 31:1165–76. doi: 10.1016/j.peptides.2010.02.022

37. Hernández-Ledesma B, Contreras M, Recio I. Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv Colloid Interface Sci. (2010) 165:23–35.

38. Fu Y, Therkildsen M, Aluko RE, Lametsch R. Exploration of collagen recovered from animal by-products as a precursor of bioactive peptides: successes and challenges. Crit Rev Food Sci Nutr. (2019) 59:2011–27. doi: 10.1080/10408398.2018.1436038

39. Yokoyama K, Chiba H, Yoshikawa M. Peptide inhibitors for angiotensin I-converting enzyme from thermolysin digest of dried bonito. Biosci Biotechnol Biochem. (1992) 56:1541–5. doi: 10.1271/bbb.56.1541